Table 2 Characteristics associated with visits to the emergency department (ED) (n = 10,061)
Characteristic | Value |
|---|---|
Emergency visits per patient | |
Median (IQR) | 2 (1–4) |
Mean ± SD | 3.6 ± 4.7 |
Emergency visits per patient according to cancer type | Median (IQR) |
Solid | |
Breast cancer | 2 (1–4) |
Gastrointestinal cancer | 3 (1–5) |
Prostate cancer | 2 (1–4) |
Genitourinary cancer | 2 (1–4) |
Lung cancer | 2 (1–5) |
Others | 3 (1–4) |
Hematology | |
Leukemia | 2 (1–5) |
Lymphoma | 2 (1–4) |
Multiple myeloma | 2 (1–4) |
Resulted in hospitalization, n (%) | 1414 (14%) |
Solid | 1215 (86%) |
Breast cancer | 483 (34.2%) |
Gastrointestinal cancer | 295 (20.9%) |
Prostate cancer | 63 (4.4%) |
Genitourinary cancer | 45 (3.2%) |
Lung cancer | 119 (8.4%) |
Others | 210 (14.9%) |
Hematology | 199 (14%) |
Leukemia | 55 (3.9%) |
Lymphoma | 108 (7.6%) |
Multiple myeloma | 36 (2.5%) |
Primary reason for ED visit, n (%) | |
Neuromuscular and skeletal | 3498 (34.8%) |
Gastrointestinal | 2034 (20.2%) |
Infection | 1261 (12.5%) |
Respiratory | 1244 (12.4%) |
Neurological | 595 (6%) |
Endocrine/metabolic | 358 (3.5%) |
Renal | 298 (2.9%) |
Hematologic | 242 (2.4%) |
Others | 531 (5.3%) |
Cancer treatment received prior to ED visit, n (%) | |
Monotherapy | 5602 (55.7%) |
Combination therapy | 4459 (44.3%) |
Type of systemic cancer treatment received prior to ED visit, n (%) | |
Platinum-based chemotherapy | 2490 (24.8%) |
Immune-mediated/targeted therapy | 1541 (15.3%) |
Hormonal therapies | 1241 (12.3%) |
Anthracycline-containing regimens | 1206 (12%) |
Taxanes | 1157 (11.5%) |
Others | 2426 (24.1%) |